WAM
TNGX icon

Wolverine Asset Management’s Tango Therapeutics TNGX Stock Holding History

Wolverine Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,020
Closed -$52K – 1871
2020
Q3 		$52K Buy
+5,020
New +$51.3K ﹤0.01% 1261

Other funds holding TNGX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wolverine Asset Management's TNGX Position: Q4 2020 in Review

Wolverine Asset Management sold out of Tango Therapeutics (TNGX) in Q4 2020, closing a stake of 5,020 shares — an estimated $52K sold.

Wolverine Asset Management first reported a position in TNGX in Q3 2020 and held it in 1 quarter. The position peaked at $52K in Q3 2020. 39 funds tracked by Wall St. Rank hold TNGX as of Q4 2020.

  • Wolverine Asset Management reported no remaining Tango Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wolverine Asset Management sold 5,020 Tango Therapeutics shares in Q4 2020, an estimated $52K.
  • Wolverine Asset Management first reported a position in Tango Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wolverine Asset Management's Tango Therapeutics position peaked at $52K in Q3 2020.
  • 39 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2020.

Based on Wolverine Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.